Skip to main content
SpringerLink
Log in

Peritoneal Mesothelioma: Diagnosis and Management

  • Chapter
  • First Online:
Mesothelioma

  • 528 Accesses

Abstract

Peritoneal mesothelioma (PM) is an uncommon and locally aggressive tumor encompassing a wide spectrum of biological behaviors, from clinically indolent to rapidly fatal disease. PM has been historically treated with debulking (DBK) surgery and/or palliative systemic chemotherapy (sCT), resulting in a median survival of only 1 year in the malignant variants. The biology of this disease has been poorly understood until recent years when mechanisms of resistance to therapy and new potential molecular therapeutic targets have been thoroughly investigated. Pathological and histological classifications of PM are still evolving. The clinical management of these conditions has improved during the last 30 years with the advent of a comprehensive treatment approach involving cytoreductive surgery (CRS) and intraperitoneal drug administration, such as hyperthermic intraperitoneal chemotherapy (HIPEC), resulting in increased patient survival. This review addresses relevant clinical and biological issues of PM, including molecular features, diagnosis, pathology, role of modern systemic and targeted therapies, patient selection for combined surgical treatment, surgical technique, and prognostic factors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Robinson BWS, Lake RA. Advanced in malignant mesothelioma. N Engl J Med. 2005;353:1591–603.

    Article  CAS  PubMed  Google Scholar 

  2. Conti S, Minelli G, Ascoli V, Marinaccio A, Bonafede M, Manno V, Crialesi R, Straif K. Peritoneal mesothelioma in Italy: trends and geography of mortality and incidence. Am J Ind Med. 2015;58:1050–8.

    Article  PubMed  Google Scholar 

  3. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18:985–90.

    Article  CAS  PubMed  Google Scholar 

  4. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12:605–21.

    Article  PubMed  Google Scholar 

  5. Gazdar AF, Carbone M. Molecular pathogenesis of mesotheliom and its relationship to Simian virus 40. Clin Lung Cancer. 2003;5:177–81.

    Article  PubMed  Google Scholar 

  6. Roushdy-Hammady I, Siegel J, Emri S, et al. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet. 2001;357:444–5.

    Article  CAS  PubMed  Google Scholar 

  7. Nonaka D, Kusamura S, Baratti D, et al. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer. 2005;104:2181–8.

    Article  PubMed  Google Scholar 

  8. Borczuk AC, Taub RN, Hesdorffer M, et al. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res. 2005;11:3303–8.

    Article  CAS  PubMed  Google Scholar 

  9. Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M. The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for Cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Ann Surg Oncol. 2016;23:1468–73.

    Article  PubMed  Google Scholar 

  10. Deraco M, Cabras A, Baratti D, Kusamura S. Immunohistochemical evaluation of Minichromosome maintenance protein 7 (MCM7), topoisomerase IIα, and Ki-67 in diffuse malignant peritoneal mesothelioma patients using tissue microarray. Ann Surg Oncol. 2015;22:4344–51.

    Article  PubMed  Google Scholar 

  11. Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49:3140–8. 8A.L.

    Article  PubMed  Google Scholar 

  12. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–7.

    Article  CAS  PubMed  Google Scholar 

  13. Villa R, Daidone MG, Motta R, Venturini L, De Marco C, Vannelli A, Kusamura S, Baratti D, Deraco M, Costa A, Reddel RR, Zaffaroni N. Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin Cancer Res. 2008;14:4134–40.

    Article  CAS  PubMed  Google Scholar 

  14. Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M, Erdas R, Cabras A, Kusamura S, Baratti D, Deraco M, Daidone MG. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol. 2007;29:453–66.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. De Cesare M, Sfondrini L, Pennati M, De Marco C, Motta V, Tagliabue E, Dera M, Balsari A, Zaffaroni N. CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. J Transl Med. 2016;14:25.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Perrone F, Jocollè G, Pennati M, Deraco M, Baratti D, Brich S, Orsenigo M, Tarantino E, De Marco C, Bertan C, Cabras A, Bertulli R, Pierotti MA, Zaffaroni N, Pilotti S. Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. Eur J Cancer. 2010;46:2837–48.

    Article  CAS  PubMed  Google Scholar 

  17. Churg A, Roggli VL, Galateau-Salle F, et al. Tumours of the pleura: Mesothelial tumours. In: Travis WD, Brambilla E, Harris CC, Muller-Hermelink HK, editors. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.

    Google Scholar 

  18. Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2018;142:89–108.

    Article  CAS  PubMed  Google Scholar 

  19. Battifora H, McCaughey WTE. Tumours and pseudotumours of the serosal membranes. In: Atlas of tumour pathology 3rd series, fascicle 15. Washington, DC: Armed Forces Institute of Pathology; 1995. p. 15–88.

    Google Scholar 

  20. Roggli VL, Cagle PT. Pleura, pericardium and peritoneum. In: Silverberg SG, DeLellis RA, Frable WJ, LiVolsi VA, Wick MR, editors. Silverberg’s principles and practice of surgical pathology. 4th ed. New York: Churchill-Livingstone/Elsevier; 2006. p. 1005–39.

    Google Scholar 

  21. Attanoos RL, Gibbs AR. Pathology of malignant mesothelioma. Histopathology. 1997;30:403–18.

    Article  CAS  PubMed  Google Scholar 

  22. Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco M. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2010;17:45–53.

    Article  PubMed  Google Scholar 

  23. Butnor KJ, Sporn TA, Hammar SP, Roggli VL. Well-differentiated papillary mesothelioma. Am J Surg Pathol. 2001;25:1304–9.

    Article  CAS  PubMed  Google Scholar 

  24. Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). Ann Surg Oncol. 2007;14:2790–7.

    Article  CAS  PubMed  Google Scholar 

  25. Churg A, Colby TV, Cagle P. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol. 2000;24:1183–200.

    Article  CAS  PubMed  Google Scholar 

  26. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003;43:231–8.

    Article  CAS  PubMed  Google Scholar 

  27. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med. 2005;129:1407–14.

    PubMed  Google Scholar 

  28. Cerruto CA, Brun EA, Chang D, Sugarbaker PH. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med. 2006;130:1654–61.

    PubMed  Google Scholar 

  29. de Pangher V, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol. 2010;21:348–53.

    Article  Google Scholar 

  30. Baratti D, Kusamura S, Martinetti A, Seregni E, Oliva DG, Laterza B, Deraco M. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2007;14:500–8.

    Article  PubMed  Google Scholar 

  31. Bruno F, Baratti D, Martinetti A, Morelli D, Sottotetti E, Bonini C, Guaglio M, Kusamura S, Deraco M. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: a preliminary study. Eur J Surg Oncol. 2018;44:792–8.

    Article  PubMed  Google Scholar 

  32. Park JY, Kim KW, Kwon HJ, et al. Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. Am J Roentgenol. 2008;191:814–25.

    Article  Google Scholar 

  33. Whitley N, Brenner D, Antman K, Grant D, Aisner J. CT of peritoneal mesothelioma: analysis of eight cases. Am J Roentgenol. 1982;138:531–5.

    Article  CAS  Google Scholar 

  34. Yan TD, Haveric N, Carmignani CP, Bromley CM, Sugarbaker PH. Computed tomographic characterization of malignant peritoneal mesothelioma. Tumori. 2005;91:394–400.

    Article  PubMed  Google Scholar 

  35. Yan TD, Haveric N, Carmignani CP, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer. 2005;103:839–49.

    Article  PubMed  Google Scholar 

  36. Dubreuil J, Giammarile F, Rousset P, et al. The role of 18F-FDG-PET/ceCT in peritoneal mesothelioma. Nucl Med Commun. 2017;38:312–8.

    Article  PubMed  Google Scholar 

  37. Laterza B, Kusamura S, Baratti D, Oliva GD, Deraco M. Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. In Vivo. 2009;23:187–90.

    PubMed  Google Scholar 

  38. Rogoff EE, Hilaris B, Huvos AG. Long-term survival in patients with malignant peritoneal mesothelioma treated with irradiation. Cancer. 1973;32:656–64.

    Article  CAS  PubMed  Google Scholar 

  39. Jones DEC, Silver D. Peritoneal mesothelioma. Surgery. 1979;86:556–60.

    CAS  PubMed  Google Scholar 

  40. Chahinian AP, Pajak TF, Holland JF, et al. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med. 1982;96:746–55.

    Article  CAS  PubMed  Google Scholar 

  41. Antman KH, Osteen R, Klegar K, et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet. 1985;2:977–81.

    Article  CAS  PubMed  Google Scholar 

  42. Kirmani S, Cleary SM, Mowry J, et al. Intracavitary cisplatin for malignant mesothelioma: an update. In: Proc Am Clin Oncol, vol. 7, 1988. (Abstract 1057).

    Google Scholar 

  43. van Gelder T, Hoogsteden HC, Versnel MA, et al. Malignant peritoneal mesothelioma: a series of 19 cases. Digestion. 1989;43:222–7.

    Article  PubMed  Google Scholar 

  44. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 1992;118:547–50.

    Article  CAS  PubMed  Google Scholar 

  45. Neumann V, Muller KM, Fischer M. Peritoneal mesothelioma-incidence and aetiology. Pathologe. 1999;20:169–76.

    Article  CAS  PubMed  Google Scholar 

  46. Eltabbakh GH, Piver MS, Hempling RE, et al. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol. 1999;70:6–12.

    Article  CAS  PubMed  Google Scholar 

  47. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965-1985. J Clin Oncol. 1988;6:147–53.

    Article  CAS  PubMed  Google Scholar 

  49. Chahinian AP, Antman K, Goutsou M, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the cancer and Leukemia group B. J Clin Oncol. 1993;11:1559–65.

    Article  CAS  PubMed  Google Scholar 

  50. Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma - results from the international expanded access program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64:211–8.

    Article  CAS  PubMed  Google Scholar 

  51. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.

    Article  CAS  PubMed  Google Scholar 

  52. Jänne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7:40–6.

    Article  PubMed  Google Scholar 

  53. Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008;26:3567–72.

    Article  CAS  PubMed  Google Scholar 

  54. Hesdorffer ME, Chabot JA, Keohan ML, et al. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol. 2008;31:49–54.

    Article  CAS  PubMed  Google Scholar 

  55. Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M. Diffuse malignant peritoneal mesothelioma: failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2009;16:463–72.

    Article  CAS  PubMed  Google Scholar 

  56. Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1093–100.

    Article  PubMed  Google Scholar 

  57. Kepenekian V, Elias D, Passot G, et al. Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE database: multi-institutional retrospective study. Eur J Cancer. 2016;65:69–79.

    Article  CAS  PubMed  Google Scholar 

  58. Jaquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49–58.

    Google Scholar 

  59. Baratti D, Kusamura S, Guaglio M, Deraco M. Peritoneal metastases: challenges for the surgeon. Minerva Chir. 2015;70:195–215.

    CAS  PubMed  Google Scholar 

  60. Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol. 2012;19:1416–24.

    Article  PubMed  Google Scholar 

  61. Deraco M, Baratti D, Kusamura S, Laterza B, Balestra MR. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol. 2009;100:321–8.

    Article  PubMed  Google Scholar 

  62. Bijelic L, Stuart OA, Sugarbaker PH. Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous cisplatin for diffuse malignant peritoneal mesothelioma. Gastroenterol Res Pract. 2012;2012:1–6. Article ID 890450.

    Google Scholar 

  63. Blackham AU, Shen P, Stewart JH, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol. 2010;17:1720–7.

    Article  Google Scholar 

  64. Robella M, Vaira M, Mellano A, et al. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC. Minerva Chir. 2014;69:9–15.

    CAS  PubMed  Google Scholar 

  65. Elias D, Bedard V, Bouzid T, et al. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol. 2007;31:784–8.

    Article  PubMed  Google Scholar 

  66. Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009;99:109–13.

    Article  PubMed  Google Scholar 

  67. Gilani SNS, Mehta A, Garcia-Fadrique A, et al. Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival. Int J Hyperth. 2018;34:578–84.

    Article  Google Scholar 

  68. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma—a multi-institutional registry study. J Clin Oncol. 2009;27:6237–42.

    Article  PubMed  Google Scholar 

  69. Alexander HR Jr, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153:779–86.

    Article  PubMed  Google Scholar 

  70. Hommell-Fontaine J, Isaac S, Passot G, et al. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study. Ann Surg Oncol. 2013;20:3892–8.

    Article  CAS  PubMed  Google Scholar 

  71. Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2014;21:1159–65.

    Article  PubMed  Google Scholar 

  72. Ihemelandu C, Bijelic L, Sugarbaker PH. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ann Surg Oncol. 2015;22:1680–5.

    Article  PubMed  Google Scholar 

  73. Malgras B, Gayat E, Aoun O, et al. Impact of combination chemotherapy in peritoneal mesothelioma Hyperthermic Intraperitoneal chemotherapy (HIPEC): the RENAPE study. Ann Surg Oncol. 2018;25:3271–9.

    Article  PubMed  Google Scholar 

  74. Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH, Peritoneal Surface Oncology Group. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer. 2011;117:1855–63.

    Article  PubMed  Google Scholar 

  75. Schaub NP, Alimchandani M, Quezado M, et al. A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol. 2013;20:555–61.

    Article  PubMed  Google Scholar 

  76. Cao C, Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH, Peritoneal Surface Malignancy Group. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol. 2012;23:1494–8.

    Article  CAS  PubMed  Google Scholar 

  77. Pillai K, Pourgholami MH, Chua TC, Morris DL. Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma. Am J Cancer Res. 2013;3:411–23.

    PubMed  PubMed Central  Google Scholar 

  78. Votanopoulos KI, Sugarbaker P, Deraco M, et al. Is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from the peritoneal surface oncology group international registry. Ann Surg Oncol. 2018;25:667–73.

    Article  PubMed  Google Scholar 

  79. Krasinskas AM, Borczuk AC, Hartman DJ, et al. Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma. Histopathology. 2016;68:729–37.

    Article  PubMed  Google Scholar 

  80. Valmary-Degano S, Colpart P, Villeneuve L, et al. Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: a RENAPE study. Eur J Surg Oncol. 2017;43:1915–23.

    Article  CAS  PubMed  Google Scholar 

  81. Huang Y, Alzahrani NA, Liauw W, Morris DL. Effects of sex hormones on survival of peritoneal mesothelioma. World J Surg Oncol. 2015;13:210.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Pillai K, Pourgholami MH, Chua TC, Morris DL. MUC1 has prognostic significance in malignant peritoneal mesothelioma. Int J Biol Markers. 2013;28:303–12.

    Article  CAS  PubMed  Google Scholar 

  83. Singhi AD, Krasinskas AM, Choudry HA, et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol. 2016;29:14–24.

    Article  CAS  PubMed  Google Scholar 

  84. Li YC, Khashab T, Terhune J, et al. Preoperative thrombocytosis predicts shortened survival in patients with malignant peritoneal mesothelioma undergoing operative Cytoreduction and Hyperthermic Intraperitoneal chemotherapy. Ann Surg Oncol. 2017;24:2259–65.

    Article  PubMed  Google Scholar 

  85. Chua TC, Yan TD, Deraco M, Glehen O, Moran BJ, Sugarbaker PH. Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma. Br J Surg. 2011;98:60–4.

    Article  CAS  PubMed  Google Scholar 

  86. Nizri E, Baratti D, Guaglio M, et al. Multicystic mesothelioma: operative and long-term outcomes with cytoreductive surgery and hyperthermic intra peritoneal chemotherapy. Eur J Surg Oncol. 2018;44:1100–4.

    Article  PubMed  Google Scholar 

  87. Baratti D, Kusamura S, Cabras AD, et al. Diffuse malignant peritoneal mesothelioma: incorporation of a simple pathological grading into recently proposed TNM classification improbe out come prediction. In: 9th International Congress on peritoneal Surface malignancies. Amsterdam, ND. 9-11 October 2014.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Peritoneal Surface Malignancy Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori Via Venezian, Milan, Italy

    Marcello Deraco, Shigeki Kusamura, Marcello Guaglio, Eran Nizri & Dario Baratti

  2. Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori Via Venezian, Milan, Italy

    Antonello Cabras & Eran Nizri

  3. Division of Surgery, Department of Surgery A, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv, Israel

    Eran Nizri

Authors
  1. Marcello Deraco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shigeki Kusamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marcello Guaglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonello Cabras
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eran Nizri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dario Baratti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcello Deraco .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Humanitas Gavazzeni Hospital, Bergamo, Italy

    Giovanni Luca Ceresoli

  2. Scientific Direction, Humanitas Gavazzeni Hospital, Bergamo, Italy

    Emilio Bombardieri

  3. Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy

    Maurizio D'Incalci

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Deraco, M., Kusamura, S., Guaglio, M., Cabras, A., Nizri, E., Baratti, D. (2019). Peritoneal Mesothelioma: Diagnosis and Management. In: Ceresoli, G., Bombardieri, E., D'Incalci, M. (eds) Mesothelioma. Springer, Cham. https://doi.org/10.1007/978-3-030-16884-1_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16884-1_21

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16883-4

  • Online ISBN: 978-3-030-16884-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation